drugset

drugset / Trial / NCT03685786

CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT

NCT03685786 ↗

Phase 1 Unknown 20 enrolled Shenzhen Second People's Hospital

NaSingle-groupOpen-labelTreatment

Summary

The clinical study of CART19 Cells treatment for MRD of B Cell Malignancies and then auto-HSCT

Timeline

Start: 2018-06-01
Primary completion: 2021-06-02
Completion: 2021-09-02

Publications

Zhou W, Chen W, Wan X, Luo C, Du X, Li X, Chen Q, Gao R, Zhang X, Xie M, Wang M. Benefits of Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphoma. Front Genet. 2022 Jan 20;12:815679. doi: 10.3389/fgene.2021.815679. eCollection 2021.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CART19 cell	Cell therapy	5e+07 cells	Intravenous
Subject	CART19 cell	Cell therapy	4e+08 cells	Intravenous

Indications